Evidence map›Paper›PMID 24497881›Full record

ArticleHepatitis monthly2014

Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users.

Jacqueline K Flynn, Rachel Sacks-Davis, Peter Higgs, Campbell Aitken, Sarah Moneer, Vijay Suppiah, Lilly Tracy, Rosemary Ffrench, Scott Bowden, Heidi Drummer and 3 more

Abstract read
In one paragraph

Article in Hepatitis monthly, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jacqueline K FlynnCentre for Biomedicine, Burnet Institute, Melbourne, Australia ; Department of Infectious Diseases, Monash University, Melbourne, Australia.
Rachel Sacks-DavisCentre for Population Health, Burnet Institute, Melbourne, Australia ; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Peter HiggsCentre for Population Health, Burnet Institute, Melbourne, Australia ; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia ; National Drug Research Institute, Faculty of Health Sciences, Curtin University, Melbourne, Australia.
Campbell AitkenCentre for Population Health, Burnet Institute, Melbourne, Australia ; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Sarah MoneerDepartment of Microbiology and Immunology, University of Melbourne, Parkville, Australia.
Vijay SuppiahStorr Liver Unit, Westmead Millennium Institute, University of Sydney, Sydney, Australia ; School of Pharmacy, University of South Australia, Adelaide, Australia.
Lilly TracyVictorian Infectious Diseases Reference Laboratory, North Melbourne, Australia.
Rosemary FfrenchCentre for Biomedicine, Burnet Institute, Melbourne, Australia ; Department of Immunology, Monash University, Melbourne, Australia.
Scott BowdenVictorian Infectious Diseases Reference Laboratory, North Melbourne, Australia.
Heidi DrummerCentre for Biomedicine, Burnet Institute, Melbourne, Australia ; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia ; Department of Microbiology, Monash University, Clayton, Australia.
Jacob GeorgeStorr Liver Unit, Westmead Millennium Institute, University of Sydney, Sydney, Australia.
Mandvi BharadwajDepartment of Microbiology and Immunology, University of Melbourne, Parkville, Australia.
Margaret HellardCentre for Population Health, Burnet Institute, Melbourne, Australia ; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDetectable HCV-specific cellular immune responses in HCV antibody and RNA negative people who inject drugs (PWID) raise the question of whether some are resistant to HCV infection. Immune responses from people who have been exposed to hepatitis C virus (HCV) and remain anti-HCV negative are of interest for HCV vaccine development; however, limited research addresses this area.

objectivesIn a cohort of HCV antibody and RNA negative PWID, we assessed whether the presence of HCV-specific IFN-γ responses or genetic associations provide any evidence of protection from HCV infection. PATIENTS AND

methodsOne hundred and ninety-eight participants were examined longitudinally for clinical, behavioral, social, environmental and genetic characteristics (IFNL3 genotype [formally IL-28B] and HLA type). Sixty-one of the 198 participants were HCV antibody and RNA negative, with 53 able to be examined longitudinally for HCV-specific IFN-γ ELISpot T cell responses.

resultsTen of the 53 HCV antibody and RNA negative participants had detectable HCV-specific IFN-γ responses at baseline (18%). The magnitude of IFN-γ responses averaged 131 +/- 96 SFC/106 PBMC and the breadth was mean 1 +/- 1 pool positive. The specificity of responses were mainly directed to E2, NS4b and NS5b. Participants with (10) and without (43) HCV-specific IFN-γ responses did not differ in behavioral, clinical or genetic characteristics (P > 0.05). There was a larger proportion sharing needles (with 70%, without 49%, P = 0.320) and a higher incidence of HCV (with 35.1 per 100 py, 95% CI 14.6, 84.4, without 16.0 per 100 py, 95% CI 7.2, 35.6, P = 0.212) in those with IFN-γ responses, although not statistically significant. Half the participants with baseline IFN-γ responses became HCV RNA positive (5/10), with one of these participants spontaneously clearing HCV. The spontaneous clearer had high magnitude and broad Th1 responses, favorable IFNL3 genotype and favorable HLA types.

conclusionsThis study demonstrated the detection of HCV-specific IFN-γ responses in HCV antibody and RNA negative individuals, with a tendency for HCV-specific IFN-γ responses to be associated with HCV exposure. The potential role of HCV-specific IFN-γ responses in those who remained HCV RNA negative is of value for the development of novel HCV therapeutics.

Indexed as

Cohort StudiesDrug UsersHepatitis C

Identifiers

PMID24497881
PMCPMC3909641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.